PRESS RELEASE Astellas Pharma Inc.

Anokion is definitely a biotechnology company developing products based on proprietary technology for the induction of antigen-particular immune tolerance. The technology targets antigens to the areas of red bloodstream cells in vivo; as the cells circulate, age group and so are cleared, the associated antigens are processed using the immune program’s normal mechanisms to prevent autoimmunity. Anokion’s technology provides demonstrated the ability to induce immune tolerance to proteins drugs also to autoimmune antigens in animal models. The creation of Kanyos shall enable preclinical development of products for type 1 diabetes and celiac disease. We are delighted that our partner Astellas is certainly applying its assets and pharmaceutical development experience to Anokion’s system technology and immunology knowledge, through our new company Kanyos, said Jeffrey A.DOI: 10.1016/j.stemcr.2015.09. Its concentrate areas will be the engineering sciences, organic sciences, life medicine and sciences, reinforced by colleges of administration and education. TUM functions as an entrepreneurial university that promotes talents and creates worth for society. For the reason that it earnings from having strong companions in industry and technology. In 2006 and 2012 it earned acknowledgement as a German Excellence University. In international ratings, TUM regularly places one of the better universities in Germany.

Bristol-Myers Squibb acquires Inhibitex Bristol-Myers Squibb Organization announced today the successful completion of the tender present by Bristol-Myers Squibb Organization for all the outstanding shares of common stock of Inhibitex, Inc.